ObsEva SA (NASDAQ: OBSV) Announces Two Poster Presentation at the 2021 ASRM Congress And Release of PRIMROSE Study Data

ObsEva SA (NASDAQ: OBSV) has announced two imminent poster presentations on its oral GnRH antagonist, linzagolix, at the 2021 American Society for Reproductive Medicine Scientific Congress & Expo taking place on October 17-20, 2021.

ObsEva to make presentations on October 20, 2021

The titles for the poster presentations include “Efficacy and Safety of Linzagolix for the Treatment of Severe Adenomyosis: Final Results from a Pilot Study” and “Administration of Hormonal Add-Back Therapy (ABT) Counteracts the Uterine Volume Reducing Effects of Oral GnRH Antagonist Therapy.” Jacques Donnez, a key opinion leader in gynecologic therapeutics, will make both presentations on October 20, 2021.

ObsEva focuses on the development and commercialization of new therapies to enhance reproductive health and pregnancy in women. The company formed a late-stage clinical pipeline through strategic in-licensing and disciplined drug development with programs focusing on new therapies for endometriosis, uterine fibroids, and preterm labor.

ObsEva to present PRIMROSE linzagolix study data at ASRM 2021

The company will release clinical data from Phase 3 PRIMROSE (1 and 2() linzagolix study in treating uterine fibroids and final data from the pilot trial of linzagolix in severe adenomyosis treatment at the ASRM 2021 Congress. Linzagolix is a novel oral, once-daily GnRH receptor antagonist with a possible best-in-class profile under development for uterine fibroids treatment.

Donnez said, “Enlarged uterine volume is an important driver of abnormal bleeding and pain associated with uterine fibroids; moreover, bulk and pressure symptoms may strongly impact women’s quality of life. We are encouraged by the positive data and the robust responses that were observed at the full suppression dose of linzagolix, demonstrating the potential to promote meaningful reductions in uterine volume in addition to reduction in heavy menstrual bleeding. In addition, Linzagolix is the only GnRH antagonist to provide flexible dosing options to better address the individual needs of patients, and these results further underscore its differentiated profile and potential clinical utility.”